Circular cell-permeable peptide
Novel cell-permeable peptides and endosomal escape vehicles enhance the delivery and efficacy of nucleic acid-based therapies by addressing membrane traversal and endosomal escape limitations.
JP2026121310APending Publication Date: 2026-07-23ENTRADA THERAPEUTICS INC
View PDF 0 Cites 0 Cited by
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- ENTRADA THERAPEUTICS INC
- Filing Date
- 2026-03-19
- Publication Date
- 2026-07-23
AI Technical Summary
Technical Problem
Existing nucleic acid-based therapeutic agents face challenges in efficiently delivering cargo molecules across cell membranes and overcoming endosomal escape, limiting their effectiveness in treating intracellular targets.
Method used
Development of novel cell-permeable peptides (CPPs) with improved toxicity profiles and endosomal escape vehicles (EEVs) to facilitate intracellular delivery of therapeutic agents.
Benefits of technology
Enhances the delivery efficiency of nucleic acid-based therapies by improving cellular uptake and endosomal escape, leading to effective intracellular distribution and functional outcomes.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure 2026121310000001_ABST
Abstract
To provide compositions containing novel cell-permeable peptides and peptides having appropriate toxicity profiles. [Solution] This disclosure relates to cell-permeable peptides, such as cyclic cell-permeable peptides, which have high cytoplasmic delivery efficiency and reduced toxicity, and can effectively deliver cargo into cells to treat various conditions and diseases.
Need to check novelty before this filing date? Find Prior Art